摘要
目的研究WT1基因与CD34在急性白血病(AL)中表达的相关性及其临床意义。方法采用实时定量RT-PCR方法检测92例初治AL患者骨髓细胞WT1基因的表达,同时应用流式细胞仪测定骨髓细胞CD34的表达。结果初治AL患者WT1基因、CD34表达的阳性率分别为67.4%(62/92)、44.6%(41/92),WT1基因、CD34阳性表达者的缓解率显著低于阴性表达者(P<0.01);WT1基因与CD34表达呈正相关(rn=0.5304,2χ=25.88,P<0.05);WT1+CD3+4、WT1+CD3-4、WT1-CD34-AL患者第一次缓解率比较有统计学差异(P<0.01)。结论WT1基因、CD34在AL患者骨髓细胞中的表达呈正相关,且阳性表达者的缓解率低、疗效差、预后不良。
Objective To study relation between Wilms＇ tumor gene （ WT1 ） and CD34 expression in acute leukemia （AL） cells and its clinical significance. Methods Real-time quantitative reverse transcription polymerase chain reaction （RQ-RT-PCR） was established for detecting WT1 expression levels in bone marrow cells of 92 cases of de novo AL. Flow cell meter （FCM） was used to determine CD34 expression in same 92 cases of de novo AL. Results Positive rate of WT1 and CD34 expression of de novo AL patients was 67.4% （ 62/92 ） and 44.6% （ 41/92 ） respectively; CR rate of positive group of WT1 and CD34 expression of AL patients was significantly lower titan that of negative group （P 〈0.01）. WT1 was positively related to CD34 expression in AL （ ro = 0. 5304, χ^2 = 25.88, P 〈 0.05 ）. Comparing primary CR rates of WT1 ＋ CD34^＋, WT1 ＋ CD34^- and WT1-CD34^- groups , There were significant statistic difference （P 〈 0.01）. Conclusions Expression of WT1 in bone marrow cells of AL patients is positively related to that of CD34, positive expression of them is an important factor of low CR rate, poor therapenlic effect and prognosis.
出处
《山东医药》
CAS
北大核心
2009年第13期8-10,共3页
Shandong Medical Journal
